BACKGROUND: @entity419 PET/computed tomography (CT) is now routinely used for staging and monitoring treatment response in @entity213 ( @entity213 ). Although most @entity1 with HSNCC have locoregional disease, distant metastases are relatively uncommon and occur predominantly in the lungs. AIM: To explore the potential of a limited scan range from the skull vertex to lung bases, viz. an 'above diaphragm' scan, as an adequate examination for assessment of disease following chemoradiotherapy. METHODS: A retrospective review of 240 @entity1 with @entity213 both staged and monitored after therapy with @entity419 PET/CT was conducted. @entity1 with previous @entity213 , unknown primary and known distant metastatic disease were excluded. @entity1 with positive PET/CT findings below the neck on the posttherapy study were confirmed on either follow-up clinical or radiological findings. RESULTS: A total of 196 (81.7%) @entity1 had nodal disease at PET/CT staging. Unrelated findings were present in 50 (20.8%) @entity1 , including five @entity694 and two second @entity5 . After an average of 6.4 months after staging, 13 @entity1 (5.4%) demonstrated progression to distant metastases on the posttherapy PET/CT. All @entity1 demonstrated intrapulmonary metastases. Two @entity1 had additional liver metastases, which would not have impacted on the overall management. No @entity1 demonstrated @entity66 below the diaphragm. CONCLUSION: A limited 'above-diaphragm' scan for early assessment following chemoradiotherapy may be safely considered. The benefits of this tailored approach flow onto both the health system and the @entity1 as it can improve resource allocation by increasing scanner availability and @entity1 throughput and reduces cumulative @entity1 radiation exposure.

Potential for truncating the scan length of restaging FDG-PET/CT after chemoradiotherapy in XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity419 :: ('MESH:D019788', 'Chemical') :: ['(18)F-fluorodeoxyglucose', 'Fluorine-18 fluorodeoxyglucose'] @entity66 :: ('MESH:D004194', 'Disease') :: ['isolated disease'] @entity5 :: ('MESH:D009369', 'Disease') :: ['malignancies'] @entity694 :: ('MESH:D003110', 'Disease') :: ['colonic neoplasms'] @entity213 :: ('MESH:C535575', 'Disease') :: ['head and neck squamous cell carcinoma', 'HNSCC']
@entity213 :: (MESH:C535575,Disease) :: ['head and neck squamous cell carcinoma']
